Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer
Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The ...
Struggles Getting Stakeholder Buy-In Slow AI Adoption by In-House Counsel, Users Say
Most organizations have some type of multifunctional committee set up to evaluate generative AI applications. Those ...
Struggles Getting Stakeholder Buy-in Slowing Gen AI Adoption
Most organizations have some type of multi-functional committee set up to evaluate generative AI applications. Those ...
BioPharma Dive6d
Novo’s Wegovy successor disappoints in second large trial
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Amgen (AMGN) Gets a Buy from Piper Sandler
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...